This company has been marked as potentially delisted and may not be actively trading. Oncobiologics (ONS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ONS vs. IKT, PLX, CVM, ZIVO, IZTC, CRTX, JATT, FNCH, ALVR, and AIMShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Cortexyme (CRTX), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), AlloVir (ALVR), and AIM ImmunoTech (AIM). These companies are all part of the "medical" sector. Oncobiologics vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics CEL-SCI ZIVO Bioscience Invizyne Technologies Cortexyme JATT Acquisition Finch Therapeutics Group AlloVir AIM ImmunoTech Inhibikase Therapeutics (NYSE:IKT) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk. Which has better valuation & earnings, IKT or ONS? Inhibikase Therapeutics has higher earnings, but lower revenue than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.65Oncobiologics$3.81M16.87-$38.84MN/AN/A Do analysts prefer IKT or ONS? Inhibikase Therapeutics currently has a consensus target price of $6.50, suggesting a potential upside of 275.72%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Inhibikase Therapeutics is more favorable than Oncobiologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Oncobiologics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer IKT or ONS? In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score. Company Overall Sentiment Inhibikase Therapeutics Neutral Oncobiologics Neutral Which has more risk and volatility, IKT or ONS? Inhibikase Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Do institutionals and insiders hold more shares of IKT or ONS? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Oncobiologics shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 11.5% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is IKT or ONS more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Oncobiologics -464.47%N/A -93.28% SummaryInhibikase Therapeutics beats Oncobiologics on 6 of the 11 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONS vs. The Competition Export to ExcelMetricOncobiologicsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.26M$282.90M$5.77B$9.73BDividend YieldN/AN/A6.66%4.49%P/E RatioN/AN/A82.4626.60Price / Sales16.87537.82505.10159.03Price / CashN/A22.4425.7028.92Price / Book-0.6511.8110.966.56Net Income-$38.84M-$115.81M$3.28B$266.04M Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONSOncobiologicsN/A$0.89+2.3%N/A-87.1%$64.26M$3.81M0.00N/AGap UpHigh Trading VolumeIKTInhibikase Therapeutics1.7593 of 5 stars$1.80-2.2%$6.50+261.1%+29.1%$134.13MN/A-0.676Positive NewsPLXProtalix BioTherapeutics3.3737 of 5 stars$1.55flat$15.00+867.7%+49.5%$123.59M$61.95M-11.92200CVMCEL-SCI0.4026 of 5 stars$10.43+12.0%N/A-63.1%$71.78MN/A-21.7343Short Interest ↑ZIVOZIVO Bioscience0.0716 of 5 stars$17.01flatN/A+19.3%$64.93M$15.85K-3.4910Gap DownIZTCInvizyne TechnologiesN/A$9.70flatN/AN/A$60.64MN/A0.0029News CoverageCRTXCortexymeN/A$1.60+3.9%N/A+130.9%$48.24MN/A-0.5455JATTJATT AcquisitionN/A$2.04-3.8%N/A-51.1%$35.19MN/A0.003High Trading VolumeFNCHFinch Therapeutics Group0.526 of 5 stars$13.00flatN/A-3.9%$20.88MN/A-1.47190Short Interest ↑ALVRAlloVirN/A$4.08+14.6%N/A-77.1%$20.58MN/A-0.20110Gap DownHigh Trading VolumeAIMAIM ImmunoTech0.9327 of 5 stars$2.45-3.7%$275.00+11,138.3%-92.8%$6.63M$121K-5.2120 Related Companies and Tools Related Companies IKT Alternatives PLX Alternatives CVM Alternatives ZIVO Alternatives IZTC Alternatives CRTX Alternatives JATT Alternatives FNCH Alternatives ALVR Alternatives AIM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONS) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
